Hormonal
Long-acting GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes, particularly those with established cardiovascular disease or high cardiovascular risk.
If you have type 2 diabetes and are at high risk for heart disease or have existing heart conditions, GLP-1 receptor agonists (like semaglutide or liraglutide) are strongly recommended. These medications not only help control blood sugar but also significantly reduce the risk of heart attacks, strokes, and cardiovascular death. They are considered a standard of care for cardiovascular risk mitigation in this population.
Major cardiovascular outcome trials and real-life observations have proven that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 homology, exert clinically relevant cardiovascular protection.
Why this rating
Based on multiple large-scale Cardiovascular Outcome Trials (CVOTs) and meta-analyses involving over 60,000 individuals.
Source
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Anna Solini et al. · Diabetologia · 2023
DOI 10.1007/s00125-023-05973-w
More from this paper
- Dual and triple incretin receptor agonists (e.g., tirzepatide, retatrutide) show potential for greater cardiovascular risk factor reduction than single GLP-1RAs, though definitive cardiovascular outcome trial results are pending.Limited
- GLP-1RAs reduce the risk of hospitalization for heart failure (HF) and prevent new-onset HF, although they may not reduce readmissions in patients with existing HF.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →